there's just no need to do it now. We were trying to get a sidepocket for the diagnostic or ESS. We need neither now. ESS is almost entirely paid for by CRADA and Diagnostic is a different ball game now with the triple merger. It's a good thing, whatever money we would have gotten from investors would have been at a mass dilutive cost. We need partner with cash or just to lay low, get out of the toxics, and let ESS prove itself.